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Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive
clinical responses in patients with B-cell malignancies. Critical to the success
of CAR-T cell therapies is the achievement of robust gene transfer into T cells
mediated by viral vectors such as gamma-retroviral vectors. However, current
methodologies of retroviral gene transfer rely on spinoculation and the use of
retronectin, which may limit the implementation of cost-effective CAR-T cell
therapies. Herein, a low-cost, tunable, macroporous, alginate scaffold that
transduces T cells with retroviral vectors under static condition is described.
CAR-T cells produced by macroporous scaffold-mediated viral transduction
exhibit >60% CAR expression, retain effector phenotype, expand to clinically
relevant cell numbers, and eradicate CD19+ lymphoma in vivo. Efficient
transduction is dependent on scaffold macroporosity. Taken together, the data
show that macroporous alginate scaffolds serve as an attractive alternative to
current transduction protocols and have high potential for clinical translation
to genetically modify T cells for adoptive cellular therapy.
Adoptive T cellular therapy harnesses and redirects a patient’s
own immune system and has emerged as a promising per-
sonalized treatment modality to treat cancer [1–3] and various
other diseases.[4,5] The most successful example has been the
adoptive transfer of chimeric antigen receptor redirected T cells
(CAR-T cells) targeting the CD19 expressed by B-cell malginan-
cies, that received FDA approvals in 2017.[6,7] With the com-
pelling success of CD19-specific CAR T-cell therapies, efforts
are now being directed toward broadening the application of
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CAR-T cells to other cancer types.[8–11] One
of the key steps involved in CAR T- cell ther-
apy is the genetic modification of T cells
ex vivo, which endows T cells with stable
expression of the CAR molecule that redi-
rect T-cell specificity towards tumor anti-
gens. However, inexpensive strategies to
generate large numbers of genetically mod-
ified functional T cells remains a central
challenge to the widespread use of CAR-
T cells. Thus, development of culture plat-
forms enabling ex vivo genetic engineering
of T cells followed by expansion to clinically
relevant cell numbers is of immense impor-
tance for the success of CAR-T cell therapy.
A number of different approaches are
being explored to genetically engineer T
cells ex vivo. [12–17] Among them, lentiviral
or retroviral vector-based gene transfer rep-
resents the most successful approach.[16]
When retrovirus is used to generate CAR-
T cells, T cells isolated from patients are
first stimulated with agonistic anti-CD3 and anti-CD28 anti-
bodies and then incubated with retrovirus because quiescent
T cells are refractory to retrovirus-mediated insertion.[18,19] Be-
cause of the short distance the retrovirus can travel in solu-
tion by Brownian motion (less than 600 µm within one half-
life),[20,21] activated T cells and retrovirus must be brought into
contact either by spinoculation in the presence of transduction-
promoting agents such as retronectin or polybrene or by us-
ing microfluidic based transduction devices.[22–24] Transduction-
promoting agents like polybrene[25] and protamine sulfate[26,27]
as well as microfluidic transduction devices have been used
with modest success,[28] while recombinant fibronectin fragment
CH296 (Retronectin) represents the most widely clinically used
transduction-promoting reagent for retrovirus.[29] Retronectin
binds retrovirus through its heparin-binding domain and T cells
via CS-1/RGD domains, bringing cells and retrovirus together
and facilitating gene transfer.[30] Retronectin must be pre-coated
onto a solid surface, such as polystyrene plate, flask or bag for
effective co-localization of retrovirus and T cells.[30,31] Even then,
gene transfer and subsequent CAR expression remain subopti-
mal under passive/static conditions.[32] To achieve high gene ex-
pression, retrovirus is seeded on retronectin-coated surfaces and
centrifuged at high speed.[32–34] Furthermore, retronectin is a re-
combinant protein, and it is inherently bioreactive which can in-
fluence cell differentiation and proliferation.[35,36] Thus the de-
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Figure 1. Dry macroporous scaffolds mediate retroviral transduction of human activated T cells. A) Schematic showing the preparation of macroporous
alginate scaffolds. B,C) SEM images of dry macroporous scaffolds. D) GFP expression in activated T cells transduced with equal amounts of retrovirus
seeded on dry macroporous scaffolds (red) and retronectin-coated plates with spinoculation (blue). Non-transduced control cells are represented in
black. E) SEM image of dry nanoporous scaffold. F) GFP expression in T cells transduced with retrovirus seeded on dry macroporous scaffolds (red),
hydrated macroporous scaffolds (purple), and dry nanoporous scaffolds (green). Control non-transduced cells are in black. G) Quantification of GFP+
cells (***p < 0.0001 with respect to dry macroporous scaffolds, Student’s t-test)
step ex vivo engineering process of T cells under static conditions
without retronectin or spinoculation would significantly reduce
the cost of CAR-T cell manufacturing when retrovirus is used as
gene delivery system.
We have developed a 3D macroporous scaffold as an efficient,
single-step, static platform to engineer T cells with viral vectors.
We hypothesized that 3D dimensional scaffolds with macrop-
orosity and high capacity to absorb water [37] would allow colocal-
ization of retrovirus and T cells as achieved by using retronectin.
We prepared macroporous scaffolds from calcium-crosslinked al-
ginate, which is a GMP-compliant and FDA-approved biomate-
rial extensively used for many biomedical applications due to its
biocompatibility, low toxicity, low cost, and mild gelation by diva-
lent cations.[38] We observed that dry, hygroscopic, and macrop-
orous alginate scaffolds facilitate the interaction of retrovirus and
T cells and enables efficient gene transfer in a single step without
spinoculation and without affecting functionality and viability of
engineered T cells. Thus, these scaffolds represent a simple, cost-
effective and tunable platform technology for generating highly
functional T cells for adoptive cellular therapy.
The macroporous alginate scaffolds were prepared by mild
cryogelation (Figure 1A). Imaging by scanning electron mi-
croscopy (SEM) revealed well connected, 100–200 µm pores
throughout the scaffold (Figure 1B,C). Alginate scaffolds were
tested for human T cell transduction using gamma retrovirus. T
cells obtained from the peripheral blood (PBMCs) of the three dif-
ferent health donors were activated with agonistic anti-CD3 and
anti-CD28 antibodies. Activated T cells were then seeded on ei-
ther conventional spinoculated retrovirus- and retronectin-coated
plates or retrovirus seeded into the alginate scaffolds. A prelim-
inary screen of transduction efficiency at multiplicities of infec-
tion (MOIs) of 1, 2, and 4 (Figure S1, Supporting Information) us-
ing retrovirus encoding GFP demonstrated efficient transduction
and an MOI of 2 was chosen for further experiments. As shown in
Figure 1D, 72 h after incubation with equal amounts of retrovirus
(MOI 2), T cells expressing GFP on the scaffolds were compara-
ble to those transduced by retronectin coated plates with spinocu-
lation (85 ± 3% versus 90 ± 5% GFP+ cells). For reasons not com-
pletely understood, these results showed improved transduction
in both groups as compared to viral transduction in the prelimi-
nary experiments (Figure S1, Supporting Information, 49% ver-
sus 73.5%, respectively). Despite this, very little variability was
noted across three different PBMC donors (Figure 1D).
To evaluate whether the macroporosity of the scaffolds af-
fects the interaction between retrovirus and T cells, we fabricated
nanoporous scaffolds (Figure 1E), which can absorb retrovirus
and T cells, but lack the macroporosity that permits T cell en-
try into the scaffold. To test whether the sponge-like effect was 
also needed to create proximity between retrovirus and T cells, 
we tested hydrated macroporous scaffolds, which have the large 
pores, but lack the active flow of fluid into the internal pores. 
We found that neither the dry nanoporous scaffold, nor the hy-
drated macroporous gel allowed efficient gene transfer as com-
pared to dry macroporous scaffold (Figure 1F,G). In the hydrated 
macroporous scaffold, only ≈12% of cells expressed GFP, indi-
cating that absorption of virus and T cells on the scaffold permit 
physical contact between retrovirus and T cells, but not nearly as 
efficiently as the colocalization in the pores accomplished using 
the dry macroporous alginate scaffold. Future work will explore 
the use of a chemical kinetics model to further understand the 
effect of pore size on transduction efficiency of above described 
alginate scaffolds.
Next, we assessed whether the CAR-T cells generated using 
the dry macroporous scaffold were functional in vitro. For these 
experiments we used retrovirus encoding a CAR specific for the 
CD19 antigen (CD19.CAR). Activated T cells obtained from three 
healthy donors were seeded on alginate scaffolds or retronectin-
coated plates loaded with CD19.CAR retrovirus. Upon removal 
from the scaffold or retronectin, T cells were maintained in cul-
ture, and CAR expression was analyzed on day 3 and day 9 
after transduction. As shown in Figure 2A, both scaffold and 
retronectin promoted comparable transduction efficiency, and 
CAR expression remained unaltered upon expansion through 
day 9 (Figure 2A; Figure S2, Supporting Information). CAR-T 
cells were also analyzed for immune composition by flow cy-
tometry. CAR-T cells generated by conventional means or scaf-
fold showed no differences for expression of CD4, CD8, memory 
(CD45RA, CCR7) or exhaustion (PD-1, Lag3) markers (Figure 2C; 
Figures S3 and S4, Supporting Information). Next, to evalu-
ate anti-tumor effects in vitro, control non-transduced T cells 
(NT-cells) and CD19.CAR-T cells generated either by scaffold-
mediated or retronectin-mediated transduction were co-cultured 
with CD19 positive target cells (Daudi) and CD19 negative tar-
get cells (U937 CHLA-A2+). Since effector-to-target ratio is a 
strong determinant of cytolytic activity, we measured cytotoxic-
ity at two different effector-to-target ratios (1:2 and 1:5) based on 
previous literature.[39]  NT cells did not eliminate either of the 
tumor cells, while both CD19.CAR-T cells transduced using ei-
ther the scaffold or retronectin/spinoculation eliminated CD19+ 
Daudi cells (Figure 2E; Figure S5, Supporting Information), but 
not CD19− U937 cells (Figure S6, Supporting Information), in-
dicating preserved antigen specificity of redirected T cells. From 
the same co-culture experiments, cytokines were measured in su-
pernatant collected after 24 h incubation, and CD19.CAR-T cells 
released IL-2 and interferon IFN-𝛾 in response to Daudi cells (Fig-
ures 2F,G). Finally, CD19.CAR-T cells generated using both the 
scaffold and retronectin methods showed comparable prolifer-
ative capacity in response to Daudi cells (Figure 2B). Taken to-
gether, these results demonstrate that the alginate scaffold gen-
erates highly functional CAR-T cells.
The antitumor activity of CAR-T cells observed in vitro results 
was confirmed in an in vivo tumor model. Daudi cells labeled 
with firefly luciferase (FFLuc) were intravenously (i.v.) injected 
in nonobese diabetic severe combined immunodeficiency NSG 
mice, and four days later mice (n = 5) were infused i.v. with ei-
ther control non-transduced (NT) cells or CD19.CAR-T cells gen-
erated by either scaffold- or retronectin-mediated transduction.
CD19.CAR-T cells generated by either method controlled tumor
cell growth as assessed by the measurement of tumor biolumi-
nescence intensity (Figure 3B,C; Figure S7, Supporting Informa-
tion). Control of the tumor was associated with an improved over-
all survival rate (Figure 3E) and without significant toxicity as as-
sessed by changes in body weight (Figure 3D). Thus, scaffold gen-
erated CAR-T cells were as equally functional in vivo as CAR-T
cells generated by the conventional transduction with retronectin
and spinoculation. Future studies will explore the promise of
scaffold-mediated transduction of T cells to treat solid tumors.
In conclusion, we demonstrate that a biocompatible, macrop-
orous alginate scaffold is as effective in generating T cells engi-
neered with retrovirus as the commercially available retronectin
owing to its macroporosity and hygroscopic nature. The dry scaf-
fold we have developed eliminates the need for spinoculation of
plates coated with retronectin and seeded with the retroviral parti-
cles, thereby simplifying the manufacturing process. CAR-T cells
generated through static transduction on the macroporous algi-
nate gel fully maintained their functionality. These data support
the potential for the use of an easily synthesizable and low-cost
transduction platform to enable generation of highly functional T
cells for adoptive cell therapy. This simple platform is also likely
to address the need for efficient transduction methods useful
with other refractory cell types.
Experimental Section
Preparation of Macroporous Alginate Scaffold: Macroporous alginate
scaffold was prepared by a procedure reported previously.[40] A 2% so-
lution ultrapure alginate (Pronova, MVG) in water was vigorously stirred
with 4% calcium gluconate for 15 min. The resulting mixture (final cal-
cium concentration 0.01 m) was then cast in 24 well plates (1 mL per well),
frozen at −20 °C overnight, and lyophilized. The scaffold was either used
immediately or stored at 4 °C before use in in vitro or in vivo experiments.
Preparation of Dry Nanoporous Alginate Scaffold: Calcium crosslinked
alginate gel was cast in 24 well plates and allowed to gel overnight. The
gels were then subjected to multistep solvent exchange with increasing
concentrations of ethanol (10, 30, 50, 70, 90, and 100% v/v), followed by
drying with supercritical CO2.
[41]
Scanning Electron Microscopy: Dry macroporous scaffold was cut with
a sharp razor, coated with 70 nm AuPd (Au: 60%, Pd: 40%) for 10 min
at 7 nm min−1 and analyzed on Hitachi S-3200N Variable pressure SEM.
The surface morphology of the nanoporous scaffolds was analyzed by field
emission scanning electron microscopy, FESEM (Verios FE1)
Cell Lines and Retronectin-Mediated CAR-T Cell Generation: Daudi cells
expressing firefly luciferase were maintained in RPMI 1640 (Gibco) sup-
plemented with 10% fetal bovine serum (Gibco), 2 mmol L−1 GlutaMax
(Gibco), penicillin (100 units mL−1) and streptomycin (100 mg mL−1;
Gibco). All cells were maintained at 37 °C with 5% CO2. Peripheral blood
mononuclear cells were isolated from buffy coats (Gulf Coast Regional
Blood Center) using Lymphoprep medium (Accurate Chemical and Scien-
tific Corporation) and activated on plates coated with 1 mg mL−1 CD3
(Miltenyi Biotec) and CD28 (BD Biosciences) monoclonal antibodies.
GFP.encoded or CD19.CAR encoded retrovirus was prepared according
to method reported previously.[39] The viral titer was measured by stan-
dard flow cytometry assay.[42] Serially diluted viral stocks were added to
HEK293T cells. 72 h later, GFP expression was analyzed by flow cytom-
etry. Population with 5–20% GFP+ cells were used to calculate the viral
titer (transducing units per mL) using the following equation: Titer (TU
mL−1) = (initial cell count * %GFP+)/(volume of virus * dilution factor).









































































































































































Figure 2. Scaffold-generated CD19.CAR-T cells show similar functional activity to retronectin/spinoculation-derived CAR-T cells in vitro. A) CD19.CAR
expression in T cells transduced on retronectin-coated plates or on macroporous scaffolds in comparison to non-transduced control T cells (NT cells). B)
Ex vivo expansion of T cells transduced on retronectin-coated plates or on macroporous scaffolds or NT cells. C, D) Immunophenotypic composition of
CAR-T cells obtained via scaffold-mediated or retronectin/spinoculation-mediated transduction and NT cells at day 12 of culture. Analysis was performed
gating on CAR-expressing T cells except for NT cells. E) Percentage of CD19+ Daudi cells remaining (tumor cells) when co-cultured with scaffold-
generated, retronectin/spinoculation-generated CAR-T cells or control NT cells. Tumor cells and T cells were plated at 1:5 effector to target ratio. T
cells and tumor cells were quantified by flow cytometry on day 5 of co-culture. ***p < 0.0001 unpaired Student’s t-test. F) IFN-𝛾 and IL-2 release into
co-culture supernatant by scaffold-generated, retronectin/spinoculation-generated CAR-T cells, and control NT cells after 24 h of coculture with tumor
cells as assessed by ELISA. ***p < 0.0001; two-way ANOVA with Tukey correction. Data are represented as the mean ± SD from three experiments, each
derived from a different PBMC donor.
MOI was calculated as the ratio of the number of transducing viral par-
ticles used to the actual number of cells. Activated T cells (1 × 106
cells) were transduced with GFP.encoded or CD19.CAR encoded retroviral
supernatants[39] (2 mL viral supernatant with ≈1 × 106 TU mL−1, MOI:
2) on retronectin-coated 24-well plates (Takara Bio Inc.). Two days after
transduction, transduced T cells were expanded in 50% Click’s Medium
(Irvine Scientific) and 50% RPMI-1640 supplemented with 10% HyClone
fetal bovine serum (GE Healthcare), 2 mmol L−1 GlutaMax (Gibco). peni-
cillin (100 nits mL−1), and streptomycin (100 mg mL−1; Gibco) with 10 ng
mL−1 IL7 and 5 ng mL−1 of IL15 (PeproTech) for 10 to 14 days before being
used for functional assays
Scaffold-Mediated Generation of CAR-T Cells: Retroviral super-
natant containing GFP-encoded or human CD19.CAR-encoded gamma
retrovirus[39] was concentrated tenfold by Amicon centrifugation (MWCO
100 kDa, Milipore) at 4 °C, 2500 g, 15–20 min. Dry alginate scaffolds
were transferred to non-tissue culture coated 24 well plates (Falcon).
Concentrated retrovirus (2 mL of viral supernatant concentrated to
200 µL) and 1 × 106 activated T cells (isolated from Buffy coats and
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Figure 3. Scaffold-generated CD19.CAR-T cells eradicate tumors in a mouse xenograft model of lymphoma A) Experimental timeline of the lymphoma
xenograft model in NSG mice using the FFLuc-labeled CD19+ human Daudi tumor cells. B) Representative tumor bioluminescent images (BLI) of NSG
mice inoculated with Daudi cells and treated with control NT cells or treated with CD.19.CAR-T cells generated by scaffold-mediated transduction or
retronectin/spinoculation-assisted transduction. C) Kinetics of tumor growth measured by quantification of BLI. **p < 0.01 when scaffold or CAR-T cells
were compared to control NT cells, one way ANOVA. D) Body weight change and E) Survival of tumor-bearing mice treated with control NT cells or
CD19.CAR-T cells generated by scaffold-mediated or retronectin spinoculation assisted transduction. *p < 0.05, log-rank test.
activated on CD3/CD28 coated plates) in a total volume of 300 µL media
were pipetted onto each scaffold (MOI: 2, same viral amount as for
retronectin (above)). Control scaffolds were seeded with 1 × 106 activated
T cells suspended in cell culture medium. The seeded scaffolds were
incubated without any additional medium in a 5% CO2 incubator at 37
°C for 1 h, after which 1 mL of complete medium was added. After 3 days
of culture, cells were isolated from scaffolds by digesting with 1 mL 0.125
m EDTA (calcium chelator), washed twice with PBS and analyzed for GFP
expression or CD19.CAR expression by flow cytometry. More than 95% of
cells were recovered and viable.
Flow Cytometry and Antibodies: Monoclonal antibodies specific for hu-
man CD3 (APC-Cy7, 557 832), CD4 (APC-Cy7, 561 839), CD8 (PerCP-
Cy5.5, 565 310), CD20 (FITC, 555 622), CD45RA (PE, 555 489),
CD62L (BV421, 563 861), LAG3 (PE, 565 617), PD-1 (FITC, 561 035),
and TIM3 (BV421, 565 563) were purchased from BD Biosciences,
and CCR7 (FITC, FAB197F-100) from R&D Systems. An anti idio-
type scFv monoclonal antibody was used to detect the expression
of the CD19.CAR as previously described.[39] All samples were ana-
lyzed using a BD LSRII, and a minimum of 10000 events were ac-
quired per sample. Results were analyzed using FlowJo 9 (FlowJo
LLC).
Cytokine Production by CAR-T Cells: CAR-T cells were cocultured with
Daudi tumor cells at 1:5 effector to target [E:T] ratio for 24 h and the culture
supernatant was collected. IL-2 and IFN-𝛾 were quantified by ELISA using
the manufacturer’s protocol (R&D Systems).
In Vitro Cytotoxicity: Tumor cells (Daudi) were seeded at 1 × 105 cells
per well in 24-well plates. CAR-T cells normalized for transduction effi-
ciency were added at 1:5 and 1:2 Effector:Target (E:T) ratio. On day 5 of
coculture, cells were collected, and the frequency of T cells and residual
tumor (CD20+) cells were measured by flow cytometry.
In Vivo Antitumor Activity: Eight-to-ten weeks old female, non-obese
diabetic severe combined immunodeficiency NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) mice were infused with 1 × 106 FFLuc-expressing Daudi
cells intravenously. Four days after infusion, each mouse was intravenously
injected with either 4 × 106 CD19.CAR-T cells or non-transduced (NT)
cells. Tumor burden was monitored using the Xenogen-IVIS Imaging Sys-
tem. Mice were monitored for signs of discomfort and euthanized upon
losing more than 15% of initial body weight or the development of hind-
limb paresis. All procedures involving animals were done in compliance
with the University’s Institutional Animal Care and Use Committee.
Statistical Analysis: All statistical analysis was done using two-tailed
Student’s t-test, one way ANOVA or two-way ANOVA with Tukey post hoc
analysis using graph pad prism and noted in figures as * = p < 0.05, ** = 
p < 0.01, *** = p < 0.001.
Supporting Information
Supporting Information is available from the Wiley Online Library or from 
the author.
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